ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019
Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas.
Abstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Acute Neurological Complications of Brain Tumors and Immune Therapies, a Guideline for the Neuro-hospitalist.Current neurology and neuroscience reports · 2020Guideline
- Molecular regulators of thromboinflammation and angiogenesis in pediatric cancer: emerging roles of noncoding RNAs, epigenetics, and extracellular vesicles - narrative review.Annals of medicine and surgery (2012) · 2026Review
- Prognostic and histologic significances of the expression profile of membrane tissue factor for aggressive endometrial carcinomas.The oncologist · 2026Article
- Article
- IDH mutant high-grade gliomas.Frontiers in molecular neuroscience · 2025Review
- Review
- IDH inhibition in gliomas: from preclinical models to clinical trials.Nature reviews. Neurology · 2024Review
- The Role of Tissue Factor In Signaling Pathways of Pathological Conditions and Angiogenesis.Current molecular medicine · 2024Review
- Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling.Cancer cell · 2023Article
- Tissue factor (coagulation factor III): a potential double-edge molecule to be targeted and re-targeted toward cancer.Biomarker research · 2023Review
- Modeling glioblastoma complexity with organoids for personalized treatments.Trends in molecular medicine · 2023Review
- Article
- Oncogenes and cancer associated thrombosis: what can we learn from single cell genomics about risks and mechanisms?Frontiers in medicine · 2023Review
- Necrotic reshaping of the glioma microenvironment drives disease progression.Acta neuropathologica · 2022Review
- Article
- The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma.PloS one · 2022Article
- A Novel Extracellular Matrix Gene-Based Prognostic Model to Predict Overall Survive in Patients With Glioblastoma.Frontiers in genetics · 2022Article
- Association between IDH mutational status and tumor-associated epilepsy or venous thromboembolism in patients with grade II and III astrocytoma.Brain tumor pathology · 2021Article
- The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status.Brain pathology (Zurich, Switzerland) · 2021Article
- Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles.Blood advances · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Dusten UnruhDepartment of Neurological Surgery, Northwestern University, Chicago, Illinois.
Snezana MirkovDepartment of Neurological Surgery, Northwestern University, Chicago, Illinois.
Brian WrayDepartment of Biochemistry and Molecular Genetics, Northwestern University, Chicago, Illinois.
Michael DrummDepartment of Neurological Surgery, Northwestern University, Chicago, Illinois.
Jonathan LamanoDepartment of Neurological Surgery, Northwestern University, Chicago, Illinois.
Yuping D LiDepartment of Neurological Surgery, Northwestern University, Chicago, Illinois.
Qazi F HaiderDepartment of Neurological Surgery, Northwestern University, Chicago, Illinois.
Rodrigo JavierDepartment of Neurological Surgery, Northwestern University, Chicago, Illinois.
Kathleen McCortneyDepartment of Neurological Surgery, Northwestern University, Chicago, Illinois.
Amanda SaratsisDepartment of Neurological Surgery, Northwestern University, Chicago, Illinois.ORCID 0000-0002-4913-2771
Denise M ScholtensDepartment of Preventive Medicine, Northwestern University, Chicago, Illinois.
Jann N SarkariaDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
C David JamesDepartment of Neurological Surgery, Northwestern University, Chicago, Illinois.
Craig HorbinskiDepartment of Neurological Surgery, Northwestern University, Chicago, Illinois. craig.horbinski@northwestern.edu.
Northwestern University · USMayo Clinic · US
Funding
Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Daniela E Matei · 1993 to 2026
$153.9MNorthwestern University Clinical and Translational Science Institute (NUCATS)UL1TR001422 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI D'AQUILA, RICHARD · 2015 to 2023
$56.8MMEDICAL SCIENTIST TRAINING PROGRAMT32GM008152 · NIGMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ARDEHALI, HOSSEIN · 1987 to 2021
$24.0MTargeted MV-CEA as a Potent Antitumor Agent against GBMP50CA108961 · NCI · MAYO CLINIC ROCHESTER · PI O'NEILL, BRIAN PATRICK · 2004 to 2015
$22.5MSTINGing GBM: A First-in- Man Clinical Trial in Surgical Resectable Recurrent GBMP50CA221747 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Pouya Jamshidi · 2018 to 2026
$21.4MMedical Scientist Training ProgramT32GM144295 · NIGMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ALAN R HAUSER · 2022 to 2026
$9.1MTRAINING PROGRAM IN SIGNAL TRANSDUCTION AND CANCERT32CA070085 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LEONIDAS C. PLATANIAS · 1997 to 2026
$5.7MTissue Factor as a Key Determinant of IDH1 Mutant versus IDH1 Wild-type Glioma Thrombosis and MalignancyR01NS102669 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HORBINSKI, CRAIG MICHAEL · 2017 to 2021
$1.7MThe Mayo GBM Xenograft National ResourceR24NS092940 · NINDS · MAYO CLINIC ROCHESTER · PI SARKARIA, JANN N. · 2016 to 2019
$1.1MThe Significance of Isocitrate Dehydrogenase Mutations in GliomasK08CA155764 · NCI · UNIVERSITY OF KENTUCKY · PI HORBINSKI, CRAIG MICHAEL · 2011 to 2015
$857kThe role of glioblastoma derived activated leukocyte cell adhesion molecule in peripheral monocyte PD-L1 induction and immunosuppressionF30CA206413 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LAMANO, JONATHAN BALQUIEDRA · 2016 to 2019
$197kTissue Factor/Protease-Activated Receptor 2 in IDH1 wild-type and IDH1 mutant gliomasF32CA216996 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI UNRUH, DUSTEN · 2018 to 2020
$192kNCATS NIH HHS UL1 TR001422NCI NIH HHS F30 CA206413NCI NIH HHS F32 CA216996NCI NIH HHS K08 CA155764NCI NIH HHS P30 CA060553NCI NIH HHS P50 CA108961NCI NIH HHS P50 CA221747NCI NIH HHS T32 CA070085NIGMS NIH HHS T32 GM008152NIGMS NIH HHS T32 GM144295NINDS NIH HHS R01 NS102669NINDS NIH HHS R24 NS092940
Abstract
purposeGliomas with
resultsA demethylating agent, decitabine, increased
conclusionsThese data show that TF suppression is a component of IDH1
Indexed as
DNA MethylationGene Expression Regulation, NeoplasticMutationAnimalsCell Line, TumorDisease Models, AnimalEctopic Gene ExpressionEpigenesis, GeneticGene Knockdown TechniquesGliomaHumansIsocitrate DehydrogenaseMiceNeoplasm GradingProtein BindingProteomicsIDH1 protein, humanIsocitrate DehydrogenaseThromboplastin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.